Vivax Malaria
32
2
2
27
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 32 trials
100.0%
+13.5% vs benchmark
56%
18 trials in Phase 3/4
4%
1 of 27 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 27 completed trials
Clinical Trials (32)
Tafenoquine and ACTs (TADORE- Plus)
Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.
Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia
Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea
A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria
Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure
Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients
Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine
Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas
Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax
TES of Chloroquine for Pv in the Philippines in 2016
TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
Incidence of Vivax Along the Thai Burma Border
G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria
Methylene Blue Against Vivax Malaria in Ethiopia
Biomarkers of P. Vivax Relapse
Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan
Chloroquine Population Pharmacokinetics in Pre and Post-partum Women
A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan
Eight Week Primaquine Regimen for the Treatment of Vivax Malaria